Objective: To compare the pharmacokinetic profile and bioavailability of budesonide after inhalation from the Clickhaler® dry powder inhaler with the Turbuhaler® as standard. Design: Randomised, ...

Earlier and more sustained treatment of mild asthma improves control of asthma symptoms and reduces the risk of a severe exacerbation, thereby preventing lung function damage according to the results ...

AstraZeneca will discontinue the production of PULMICORT® (budesonide) 100 and 200 µg/dose HFA pMDI (pressurised metered dose inhaler) due to complex manufacturing issues related to technical aspects ...

DALLAS — Single combination inhaler treatment with budesonide-formoterol on an as-needed basis, compared with albuterol, more than halved the risk for severe asthma attacks in patients with mild ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bj53j9/pulmicort) has announced the addition of the "Pulmicort (Asthma ...

AstraZeneca is to discontinue production of the pressurised metered dose inhaler version of its asthma treatment Pulmicort as a result of manufacturing problems. AstraZeneca is to discontinue ...

It's another setback for AstraZeneca ($AZN). A U.S. court ruled against the drugmaker in a long-running patent fight over its asthma drug Pulmicort Respules. That ...

AstraZeneca (AZ) suffered another setback yesterday when a US federal court ruled that a patent for its inhaled steroid drug Pulmicort Respules was invalid. The US District Court for the District of ...

Drugs giant AstraZeneca is ending production of a pressurised metered dose inhaler version of its asthma treatment Pulmicort, which has been developed with technology partner SkyePharma.

This randomised, double-blind, double-dummy crossover study was designed to compare the pharmacokinetic profile and pulmonary bioavailability of budesonide 1000µg delivered by inhalation as a powder ...